RU2019108092A - Тиогидантоиновые антагонисты андрогеновых рецепторов для лечения рака - Google Patents

Тиогидантоиновые антагонисты андрогеновых рецепторов для лечения рака Download PDF

Info

Publication number
RU2019108092A
RU2019108092A RU2019108092A RU2019108092A RU2019108092A RU 2019108092 A RU2019108092 A RU 2019108092A RU 2019108092 A RU2019108092 A RU 2019108092A RU 2019108092 A RU2019108092 A RU 2019108092A RU 2019108092 A RU2019108092 A RU 2019108092A
Authority
RU
Russia
Prior art keywords
thiogydantoin
antagonists
cancer treatment
androgen receptors
subject
Prior art date
Application number
RU2019108092A
Other languages
English (en)
Russian (ru)
Other versions
RU2019108092A3 (enExample
Inventor
Жилль К. Биньян
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of RU2019108092A publication Critical patent/RU2019108092A/ru
Publication of RU2019108092A3 publication Critical patent/RU2019108092A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2019108092A 2016-08-22 2017-08-22 Тиогидантоиновые антагонисты андрогеновых рецепторов для лечения рака RU2019108092A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
US62/377,932 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (2)

Publication Number Publication Date
RU2019108092A true RU2019108092A (ru) 2020-09-22
RU2019108092A3 RU2019108092A3 (enExample) 2020-11-30

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019108092A RU2019108092A (ru) 2016-08-22 2017-08-22 Тиогидантоиновые антагонисты андрогеновых рецепторов для лечения рака

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019029521A1 (zh) * 2017-08-07 2019-02-14 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
SG11202108300VA (en) 2019-02-01 2021-08-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Crystal of diarylthiohydantoin compound
CN115403624B (zh) * 2022-09-30 2024-08-27 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Also Published As

Publication number Publication date
AU2017316756A1 (en) 2019-02-21
BR112019003406A2 (pt) 2019-05-21
KR20190040030A (ko) 2019-04-16
CN109640986A (zh) 2019-04-16
RU2019108092A3 (enExample) 2020-11-30
MX2019002097A (es) 2019-05-15
US20190209539A1 (en) 2019-07-11
EP3500259A1 (en) 2019-06-26
WO2018037342A1 (en) 2018-03-01
MA45992A (fr) 2019-06-26
JP2019528290A (ja) 2019-10-10
CA3034449A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MY179696A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HUE059752T2 (hu) A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek
MX2022006069A (es) Metodo para tratar glomerulopatia c3.
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
HK1251409A1 (zh) 治疗癌症的方法
CA2983456A1 (en) Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
PH12015501531A1 (en) Crenolanib for treating flt3 mutated proliferative disorders
HK1258062A1 (zh) 给予恶拉戈利的方法
SG10201808496VA (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pytido[3.4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
MY201478A (en) Antibodies and assays for detection of folate receptor 1
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
WO2017181079A3 (en) Methods for monitoring and treating cancer
RU2017105353A (ru) Соединения
HK1247622A1 (zh) 利用il-33拮抗剂来治疗局部纤维化的方法
HK1245115A1 (zh) 口腔奥曲肽与其他治疗剂联合应用
JP2016519107A5 (enExample)
WO2015116856A3 (en) Farnesoid x receptor antagonists
EP3452455A4 (en) SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
TN2015000356A1 (en) Bicyclic compounds

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20211025